Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

- Age 18 through 65 years - Has a diagnosis of ankylosing spondylitis (AS) based on the Modified New York Criteria - Has active AS, as defined by fulfillment of at least 2 of the following 3 conditions at both Screening and Baseline visits: - BASDAI score at least 4 cm - Total back pain on a visual analog scale (VAS) at least 40 mm - Morning stiffness at least 1 hr - Has inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs) as defined by the Investigator

- Has total spinal ankylosis (bamboo spine) - Has undergone spinal surgery or joint surgery involving joints assessed within 2 months prior to Baseline - Has extra-articular manifestations (i.e., psoriasis, uveitis, inflammatory bowel disease) that is not clinically stable, as defined by the Investigator's best clinical judgment, for at least 28 days prior to Baseline - Has received intra-articular joint injection(s), spinal or paraspinal injection(s) with corticosteroids within 28 days prior to Baseline - Has prior exposure to any biologic therapy with potential therapeutic impact on AS, including anti-TNF (tumor necrosis factor) therapy